From MarketBeat:



Mind Medicine (MindMed) Inc.’s CFO, Schond L. Greenway, sold 5,652 shares of the company’s stock, valued at $3.63 per share, for a total transaction of $20,516.76. This news caused the company’s stock to rise by a significant 7.5%. MindMed’s shares are currently trading at $3.87. The company’s market cap stands at $155.19 million, and it has a PE ratio of -2.06 and a beta of 2.40.

Institutional investors and hedge funds have shown interest in Mind Medicine, with institutions including Royal Bank of Canada and Qube Research & Technologies Ltd purchasing shares, while analysts have rated the stock as a “buy.” MindMed is a clinical stage biopharmaceutical company that develops products to treat brain disorders.

Overall, the company seems to have attracted interest from both individual and institutional investors, and analysts are optimistic about its future, rating it as a “buy” with an average target price of $23.50.



Read more: Schond L. Greenway Sells 5,652 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock